^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    2d
    Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=19, Completed, Roswell Park Cancer Institute | Terminated --> Completed
    Trial completion
    |
    Photofrin (porfimer sodium)
    2d
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Peking University First Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CA9 (Carbonic anhydrase 9)
    3d
    Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) (clinicaltrials.gov)
    P3, N=705, Completed, PharmaMar | Active, not recruiting --> Completed
    Trial completion
    |
    irinotecan • topotecan • Zepzelca (lurbinectedin)
    3d
    Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Jiangmen Central Hospital
    New P2 trial
    |
    cisplatin • carboplatin • etoposide IV • AiRuiLi (adebrelimab)
    4d
    Quantitative dissection of the metastatic cascade at single colony resolution. (PubMed, bioRxiv)
    This work establishes a scalable and quantitative platform for mapping the metastatic fitness landscape at single-colony resolution across hundreds of thousands of in vivo data points. Our approach offers a broadly applicable framework for dissecting the interactions between cancer-intrinsic and microenvironmental factors governing tumor initiation, progression, and therapeutic response.
    Journal
    |
    CREBBP (CREB binding protein)
    4d
    Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (clinicaltrials.gov)
    P2, N=14, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib)
    4d
    DOTATOC PET/CT for Imaging NET Patients (clinicaltrials.gov)
    P=N/A, N=800, Active, not recruiting, British Columbia Cancer Agency | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    4d
    CBX-12-101: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=69, Completed, Cybrexa Therapeutics | Active, not recruiting --> Completed | N=130 --> 69 | Trial primary completion date: Mar 2025 --> Jun 2025
    Trial completion • Enrollment change • Trial primary completion date • First-in-human
    |
    alphalex-exatecan (CBX-12)
    5d
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (clinicaltrials.gov)
    P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Jiataile (sacituzumab tirumotecan)
    5d
    Ribonucleotide reductase regulatory subunit M2 as a macromolecular target bridging small cell lung cancer progression and SARS-CoV-2 infection. (PubMed, Int J Biol Macromol)
    Molecular docking revealed strong binding of RRM2 to SARS-CoV-2 3CLpro (-21.0 kcal/mol), while the RRM2 inhibitor COH29 exhibited superior affinity compared with Triapine and showed robust stability in molecular dynamics simulation. These findings indicate heightened vulnerability of SCLC patients to adverse COVID-19 outcomes and implicate RRM2 as a potential molecular link between aggressive tumor biology and virus-associated host susceptibility.
    Journal
    |
    RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CCNB2 (Cyclin B2) • UBE2C (Ubiquitin Conjugating Enzyme E2 C)
    |
    Triapine (3-AP) • COH29
    5d
    Structure-based design and optimization of cyclic peptide ligands targeting delta-like ligand 3. (PubMed, RSC Adv)
    The most significant improvement was achieved by substituting Val4 with rigid 1-aminocyclopropanecarboxylic acid, which produced the lead peptide B5 with a K D of 12.3 nM. These results validate our rational design strategy and identify peptide B5 as a promising candidate for the future development of DLL3-targeted theranostic agents.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    5d
    Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China. (PubMed, Front Pharmacol)
    Affordability constraints are more stringent in China than in the United States. These findings inform value-based pricing, reimbursement negotiations, and equitable access strategies.
    Journal • HEOR • Cost-effectiveness
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imdelltra (tarlatamab-dlle)